IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy

CompletedOBSERVATIONAL
Enrollment

634

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Carcinoma, Non-Small-Cell Lung
Trial Locations (37)

D4194C00003

Research Site, Aichi

Research Site, Akita

Research Site, Aomori

Research Site, Chiba

Research Site, Fukuoka

Research Site, Fukushima

Research Site, Gifu

Research Site, Gunma

Research Site, Hiroshima

Research Site, Hokkaido

Research Site, Hyōgo

Research Site, Ibaraki

Research Site, Ishikawa

Research Site, Kagawa

Research Site, Kanagawa

Research Site, Kumamoto

Research Site, Kyoto

Research Site, Mie

Research Site, Miyagi

Research Site, Miyazaki

Research Site, Nagano

Research Site, Nagasaki

Research Site, Nara

Research Site, Niigata

Research Site, Okayama

Research Site, Osaka

Research Site, Saitama

Research Site, Shiga

Research Site, Shizuoka

Research Site, Tochigi

Research Site, Tokyo

Research Site, Tottori

Research Site, Toyama

Research Site, Yamagata

Research Site, Yamaguchi

Research Site, Yamanashi

Unknown

Research Site, Ishikawa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT03643484 - IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy | Biotech Hunter | Biotech Hunter